UK markets open in 6 hours 15 minutes

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
68.86-0.36 (-0.52%)
At close: 4:00PM EDT
69.00 +0.14 (0.20%)
After hours: 04:02PM EDT

Galapagos NV

Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
http://www.glpg.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1,328

Key executives

NameTitlePayExercisedYear born
Mr. Onno Van De StolpeCo-Founder, Chairman of the Management Board, MD & CEO1.06MN/A1959
Mr. Bart Filius M.B.A., MBAPres, COO & Member of Management Board678.16kN/A1970
Dr. Andre HoekemaChief Bus. Officer & Member of Management Board610.44kN/A1957
Dr. Piet WigerinckChief Scientific Officer & Member of Management Board646.86kN/A1964
Dr. Walid Abi-SaabChief Medical Officer & Member of Management Board647.52kN/A1965
Mr. Michele Manto M.B.A.Chief Commercial Officer & Member of Management Board529.71kN/AN/A
Ms. Elizabeth GoodwinVP of Investor RelationsN/AN/AN/A
Ms. Carmen VroonenGlobal Head Communications & Public AffairsN/AN/AN/A
John MontanaManaging Director of ArgentaN/AN/AN/A
Ms. Chantal TassetHead of Devel.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

Corporate governance

Galapagos NV’s ISS governance QualityScore as of 1 June 2021 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.